HIV-1 infection can be effectively controlled by HAART, which improves the quality of lives of infected individuals, but fails
to completely eradicate the virus, even after decades of treatment. This issue, together with the emergence of multi-drug-resistant viruses,
clearly underscores the continuing need to find novel agents able to target vulnerable steps in the viral replication cycle. HIV transcriptional
regulation is a crucial step required to re-initiate viral replication from post-integration latency after interruption of therapy and to
keep the virus in circulation. In this step, the viral protein Tat plays a central role by dramatically increasing the production of elongated
transcripts through its unique interaction with the viral TAR RNA and the cellular cofactor P-TEFb, together with a myriad of other host
factors which are recruited to the viral promoter to ensure efficient transcription. The transcriptional machinery, involving an intricate interplay
of many viral and cellular components, offers a plethora of potential therapeutic targets that have not yet been exploited by any of
the antiretroviral drugs used in therapy.
In this review we explore the state-of-the-art of Tat-mediated transcription inhibitors which target the well-consolidated Tat/TAR/PTEFb
axis, together with novel therapeutics that interfere with various host-cell factors, including some pioneer inhibitors designed on
the basis of recent molecular and structural studies.
Keywords: HIV-1, Tat, TAR, P-TEFb, transactivation, latency, transcription inhibitors, small molecules
Rights & PermissionsPrintExport